Testing a new drug for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a new drug called SYS6010 to standard chemotherapy for people with a type of esophageal cancer that has progressed after initial treatment. It aims to see if SYS6010 is more effective and safe, potentially offering a new option for those who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of squamous cell carcinoma of the esophagus that cannot be removed with surgery, has come back, or has spread to other parts of the body.
- You must have tried at least one prior treatment (like chemotherapy) and it either stopped working or caused unacceptable side effects.
- You must be able to carry out daily activities (ECOG score 0 or 1) and have an expected survival of at least 3 months.
- You cannot have had certain previous treatments (like irinotecan or an ADC drug that targets topoisomerase I), and you must not have certain active infections or serious medical conditions.
- Your organs (like heart, liver, kidneys) must be functioning well enough, and you must be willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new drug (SYS6010), an immunotherapy called enlonstobart, and standard chemotherapy as the first treatment for esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug called FH-006 against standard chemotherapy for people with advanced esophageal cancer that has stopped responding to previous treatment. The goal is to see if FH-006 can help control the cancer better or with fewer side effects.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Hear when a new Locally Advanced/Metastatic/Recurrent ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.